,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-11-15 05:00:00,Warner Chilcott' s ( WCRX) third quarter 2012 earnings (excluding special items) of 99 cents per share handsomely beat the Zacks Consensus Estimate of 78 cents and the year-ago earnings of 89 cents per share.,0.9473839402198792,0.03005131520330906,0.022564832121133804,positive,0.917332649230957
1,2012-11-15 05:00:00,"Lower selling, general & administrative costs boosted earnings in the reported quarter.",0.9461169838905334,0.026632115244865417,0.027250895276665688,positive,0.9194848537445068
2,2012-11-15 05:00:00,Revenues in the reported quarter declined 7% to $606 million.,0.016691816970705986,0.9739723801612854,0.009335838258266449,negative,-0.9572805762290955
3,2012-11-15 05:00:00,"The decline was primarily attributable to lower sales of its osteoporosis drug, Actonel -- acquired from Procter & Gamble Co. ( PG ) in 2009 -- due to generic competition.",0.018956167623400688,0.9658289551734924,0.015214857645332813,negative,-0.9468727707862854
4,2012-11-15 05:00:00,"Moreover, reduced sales of dermatological product Doryx also hurt revenues in the reported quarter.",0.017831280827522278,0.972633421421051,0.009535307064652443,negative,-0.9548021554946899
5,2012-11-15 05:00:00,"Revenues, however, beat the Zacks Consensus Estimate of $601 million

Revenues from osteoporosis products declined 22% to $138 million.",0.025730416178703308,0.964047908782959,0.010221690870821476,negative,-0.9383174777030945
6,2012-11-15 05:00:00,Actonel sales declined 28% to $119 million.,0.016961941495537758,0.9721748232841492,0.010863187722861767,negative,-0.9552128911018372
7,2012-11-15 05:00:00,The loss of patent exclusivity of the drug in Western Europe in December 2010 hurt revenues in the quarter.,0.017918016761541367,0.9723953604698181,0.009686625562608242,negative,-0.9544773697853088
8,2012-11-15 05:00:00,Bulk of the revenues (64.7%) came from the US market.,0.014211797155439854,0.01058002095669508,0.9752081632614136,neutral,0.003631776198744774
9,2012-11-15 05:00:00,US sales of the drug were down 7% in the third quarter of 2012 due to a 36% decrease in filled prescriptions.,0.017330745235085487,0.9725905656814575,0.0100786741822958,negative,-0.9552597999572754
10,2012-11-15 05:00:00,"Warner Chilcott, which expects Actonel sales to continue declining, believes that osteoporosis therapy Atelvia (launched in December 2010) will help to counter loss of revenues from Actonel in the US.",0.2846342623233795,0.6682054400444031,0.04716037958860397,negative,-0.38357117772102356
11,2012-11-15 05:00:00,"Atelvia contributed $19 million to total revenue in the third quarter of 2012, up 18.8% sequentially.",0.9475032091140747,0.01471644826233387,0.037780337035655975,positive,0.932786762714386
12,2012-11-15 05:00:00,Revenues from oral contraceptives inched up 1% to $131 million.,0.9527023434638977,0.020832588896155357,0.026465101167559624,positive,0.9318697452545166
13,2012-11-15 05:00:00,An increase of 43% in the sales of Lo Loestrin FE (launched in the US in 2011) to $33 million more than mitigated the 8.7% decline in the sales of Loestrin 24 FE.,0.9506585001945496,0.03086196444928646,0.018479518592357635,positive,0.9197965264320374
14,2012-11-15 05:00:00,Sales of Loestrin 24 FE declined due to lower filled prescriptions coupled with an increase in sales-related deductions.,0.018861042335629463,0.9697876572608948,0.011351240798830986,negative,-0.9509266018867493
15,2012-11-15 05:00:00,"Sales of hormone therapy products climbed 10% to $56 million in the third quarter of 2012, driven by increased sales of Estrace cream (up 7% to $45 million).",0.955586314201355,0.01999499835073948,0.024418650195002556,positive,0.9355913400650024
16,2012-11-15 05:00:00,A 13% increase in filled prescriptions along with higher average selling prices led to the rise in Estrace cream sales in the reported quarter.,0.9514710307121277,0.020122479647397995,0.02840648777782917,positive,0.9313485622406006
17,2012-11-15 05:00:00,Sales of dermatological product Doryx declined 31% to $20 million.,0.017175110056996346,0.973254382610321,0.009570403024554253,negative,-0.9560792446136475
18,2012-11-15 05:00:00,Generic competition and an increase in sales-related deductions hurt sales of the drug during the reported quarter.,0.01866462267935276,0.9699244499206543,0.011410924606025219,negative,-0.9512598514556885
19,2012-11-15 05:00:00,"We remind investors that on April 30, 2012, a US district court issued a verdict regarding Mylan ( MYL ) and Impax Laboratories ' ( IPXL ) applications to the US Food and Drug Administration (FDA) to sell their generic versions of the drug.",0.4237290322780609,0.31876569986343384,0.2575052082538605,positive,0.10496333241462708
20,2012-11-15 05:00:00,The court ruled that the generic versions of neither of the companies infringed the patent of Doryx.,0.07237081974744797,0.6412078738212585,0.2864212691783905,negative,-0.56883704662323
21,2012-11-15 05:00:00,"Sales of gastroenterology product Asacol and urology product Enablex were more or less flat at $191 million and $45 million, respectively.",0.016702963039278984,0.9653359055519104,0.017961127683520317,negative,-0.9486329555511475
22,2012-11-15 05:00:00,"Selling, general and administrative (SG&A) expenses were down 15% in the reported quarter to $183 million.",0.016670899465680122,0.9722996950149536,0.011029372923076153,negative,-0.9556288123130798
23,2012-11-15 05:00:00,"The decline was attributable to cost savings as a result of the move to the distributor model in Western Europe, reduced co-promotion expenses as a result of lower Actonel sales in ex-US markets and a reduction in the US field sales forces.",0.14912976324558258,0.8318494558334351,0.019020745530724525,negative,-0.6827197074890137
24,2012-11-15 05:00:00,Research and development (R&D) costs declined 3.8% to $25 million in the third quarter of 2012.,0.020977485924959183,0.9690119028091431,0.010010638274252415,negative,-0.948034405708313
25,2012-11-15 05:00:00,"Apart from announcing its third quarter 2012 results, Warner Chilcott upped its 2012 adjusted earnings guidance.",0.7572944164276123,0.05099755525588989,0.19170799851417542,positive,0.7062968611717224
26,2012-11-15 05:00:00,The company now expects adjusted earnings in the range of $3.75-$3.85 per share (previous guidance: $3.55-$3.65).,0.20470331609249115,0.00942245777696371,0.7858742475509644,neutral,0.19528086483478546
27,2012-11-15 05:00:00,The company also trimmed its guidance for SG&A expenses to $725-$775 million (previous guidance: $775-$825 million).,0.09361817687749863,0.7116734981536865,0.19470831751823425,negative,-0.6180553436279297
28,2012-11-15 05:00:00,"Cost savings due to the restructuring of the company's operations in Western European nations such as Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the UK contributed to the reduced guidance.",0.020084457471966743,0.9646678566932678,0.01524774543941021,negative,-0.9445834159851074
29,2012-11-15 05:00:00,R&D expenses are now projected in the range of $90-$110 million (previous guidance: $100-$120 million).,0.017113396897912025,0.017055077478289604,0.9658315181732178,neutral,5.8319419622421265e-05
30,2012-11-15 05:00:00,Warner Chilcott continues to expect revenues in the range of $2.4 billion and $2.5 billion.,0.1999993771314621,0.00678326515480876,0.7932173013687134,neutral,0.19321611523628235
31,2012-11-15 05:00:00,The Zacks Consensus Estimate currently hints at earnings of $3.88 per share on revenues of $2.49 billion for 2012.,0.1447412520647049,0.011127359233796597,0.8441314101219177,neutral,0.13361389935016632
32,2012-11-15 05:00:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
33,2012-11-15 05:00:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
